Recipharm commits SEK5m to bioanalysis lab citing lack of Nordic capacity

By Gareth Macdonald contact

- Last updated on GMT

Recipharm commits SEK5m to bioanalysis lab citing lack of Nordic capacity

Related tags: Sweden

Recipharm has said it will spend SEK5m ($567,000) on a bioanalysis laboratory in Sweden citing the lack of capacity in the Nordic region as a driver for the investment.

The contract manufacturing firm said it will build the new lab at a site in Uppsala, Sweden, explaining that the facility will have capacity to process 10,000 plasma samples a week.

Fredrik Lehmann, General Manager at Recipharm Development in Uppsala told us the laboratory will offer a range of bioanalysis services, with a focus on the assessment of clinical and toxicology samples.

He added that the site will conduct bioanalysis work for a variety of drug types “mostly small molecule, but not exclusively, some large molecules will also be handled​.”

Nordic capacity

Sweden is a base of operations for some of the largest drug manufacturers in the world. For example, Pfizer and AstraZeneca both have production operations in the country.

But there is a lack of good laboratory practice (GLP) standard bioanalysis labs in Sweden and across the Nordic region as a whole according to Lehmann, who cited the shortage alongside customer demand as a driver for the investment.

Some major pharma might, or might not, have capacity in-house, but looking at all the GLP certificates that are issued in Sweden, there are not that many​” he said, adding that “and the majority of those GLP labs do not perform bioanalysis.”

At present Recipharm contracts bioanalysis work to a third party laboratory. However, according to Lehmann “we will not continue working with that vendor now that we have the capacity in-house​.”

The firm plans to recruit several chemists in the coming months and aims to more than double its team of 35 in the next couple of years.

Related topics: Bio Developments, Bio-Outsourcing

Related products

show more

High quality excipients and formulation support

High quality excipients and formulation support

Roquette Pharma Solutions | 09-Nov-2021 | Product Brochure

As the world grapples with the effects of ongoing health crises, the market is expanding quickly as developers shift their focus to proactive therapeutics....

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us

Products

View more

Webinars